Dipòsit Digital de Documents de la UAB 157 registres trobats  1 - 10següentfinal  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
2.
14 p, 670.4 KB Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies : Spanish Expert Consensus Recommendations / Boqué, Concepción (Hospital Duran i Reynals (Hospitalet del Llobregat)) ; Sánchez-Ramón, Silvia (Hospital Clínico San Carlos (Madrid)) ; Cordoba, Raul (Department of Hematology. Hospital Universitari Fundación Jimenez Diaz) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cabezudo, Elena (ICO-Hospital de Sant Joan Despí Moisès Broggi)
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. [...]
2023 - 10.3390/jcm12196356
Journal of clinical medicine, Vol. 12 Núm. 19 (october 2023) , p. 6356  
3.
13 p, 2.8 MB Trends in socioeconomic inequalities in mortality in small areas of 33 Spanish cities / Marí-Dell'Olmo, Marc 1978- (Institut d'Investigació Biomèdica Sant Pau) ; Gotsens, Mercè (Institut d'Investigació Biomèdica Sant Pau) ; Palència, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Rodríguez-Sanz, Maica (Institut d'Investigació Biomèdica Sant Pau) ; Martinez-Beneito, Miguel A. (Fundacion Para El Fomento de la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana) ; Ballesta, Mónica (Murcia Regional Health Council) ; Calvo, Montse (Estudios e Investigación Sanitaria) ; Cirera, Lluís (Murcia Regional Health Council) ; Daponte, Antonio (Escuela Andaluza de Salud Pública (EASP)) ; Domínguez-Berjón, Felicitas (Subdirección de Promoción de la Salud y Prevención. Consejería de Sanidad) ; Gandarillas, Ana (Subdirección de Promoción de la Salud y Prevención. Consejería de Sanidad) ; Goñi, Natividad Izco (Consejería de Salud y Servicios Sociales) ; Martos, Carmen (Instituto de Investigación Sanitaria de Aragón) ; Moreno-Iribas, Conchi (Instituto de Salud Pública de Navarra) ; Nolasco, Andreu (Universidad de Alicante) ; Salmerón, Diego (Murcia Regional Health Council) ; Taracido, Margarita (Universidad de Santiago de Compostela) ; Borrell i Thió, Carme (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
In Spain, several ecological studies have analyzed trends in socioeconomic inequalities in mortality from all causes in urban areas over time. However, the results of these studies are quite heterogeneous finding, in general, that inequalities decreased, or remained stable. [...]
2016 - 10.1186/s12889-016-3190-y
BMC public health, Vol. 16 Núm. 1 (29 2016) , p. 663  
4.
9 p, 442.2 KB B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy / Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ; Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ; Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ; Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ; Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ; Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073  
5.
10 p, 685.7 KB Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study / Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Tam, Constantine S. (Monash University) ; Grigg, Andrew (Austin Hospital) ; Scarfò, Lydia (Università Vita Salute San Raffaele) ; Kipps, Thomas J. (University of California. Moores Cancer Center) ; Srinivasan, Srimathi (Janssen Research & Development) ; Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ; Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309  
6.
9 p, 500.3 KB Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL / Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Hillmen, Peter (St James Institute of Oncology) ; O'Brien, S. (MD Anderson Cancer Center) ; Barrientos, J.C. (Hofstra Northwell School of Medicine) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S.E. (Stanford University) ; Tam, C.S. (Peter MacCallum Cancer Centre. St Vincent's Hospital) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Medical University of Vienna) ; Barr, P.M. (University of Rochester Cancer Center) ; Furman, R.R. (New York Presbyterian Hospital) ; Kipps, Thomas J (UCSD Moores Cancer Center) ; Cymbalista, F. (Hôpital Avicenne) ; Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ; Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ; Delgado, J. (Hospital Clínic i Provincial de Barcelona) ; Montillo, M. (Niguarda Hospital) ; DeVos, S. (David Geffen School of Medicine at UCLA) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Pagel, J.M. (Swedish Cancer Institute) ; Munir, Talha (St James Institute of Oncology) ; Burger, Jan A (MD Anderson Cancer Center) ; Chung, D. (Pharmacyclics LLC. AbbVie Company) ; Lin, J. (Pharmacyclics LLC. AbbVie Company) ; Gau, L. (Pharmacyclics LLC. AbbVie Company) ; Chang, B. (Pharmacyclics LLC. AbbVie Company) ; Cole, G. (Pharmacyclics LLC. AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. AbbVie Company) ; James, D.F. (Pharmacyclics LLC. AbbVie Company) ; Byrd, J.C. (Ohio State University) ; Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91  
7.
8 p, 393.1 KB Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project / Rawstron, Andy C. (St. James's Institute of Oncology) ; Kreuzer, Karl-Anton (Universitätsklinikum Köln) ; Soosapilla, Asha (Laverty Pathology) ; Spacek, Martin (University Hospital) ; Stehlikova, Olga (University Hospital Brno (República Txeca)) ; Gambell, Peter (Peter MacCallum Cancer Centre) ; McIver-Brown, Neil (Royal Bournemouth Hospital) ; Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ; Psarra, Katherina (Evangelismos Hospital) ; Arroz, Maria (C.H.L.O. Hospital S. Francisco Xavier) ; Milani, Raffaella (Ospedale San Raffaele) ; de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Cedena, M.Teresa (Hospital 12 de Octubre (Madrid)) ; Jaksic, Ozren (Dubrava University Hospital) ; Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Rigolin, Gian Matteo (St. Anna University Hospital) ; Cuneo, Antonio (St. Anna University Hospital) ; Johansen, Preben (Aalborg Universitet) ; Johnsen, Hans E. (Aalborg Universitet) ; Rosenquist, Richard (Uppsala University) ; Niemann, Carsten Utoft (Copenhagen University Hospital) ; Kern, Wolfgang (MLL Munich Leukemia Laboratory) ; Westerman, David (University Hospital Brno (República Txeca)) ; Trneny, Marek (University Hospital) ; Mulligan, Stephen (Laverty Pathology) ; Doubek, Michael (Masaryk University) ; Pospisilova, Sarka (Masaryk University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Oscier, David (Royal Bournemouth Hospital) ; Hallek, Michael (Universitätsklinikum Köln) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Montserrat, Emili (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. [...]
2018 - 10.1002/cyto.b.21595
Cytometry Part B - Clinical Cytometry, Vol. 94 Núm. 1 (january 2018) , p. 121-128  
8.
9 p, 613.6 KB Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia : Primary analysis of the randomized, open-label mable study / Michallet, Anne-Sophie (CLCC Centre Léon Bérard) ; Aktan, Melih (Istanbul University) ; Hiddemann, Wolfgang (Ludwig- Maximilians University of Munich) ; Ilhan, Osman (Ankara University School of Medicine) ; Johansson, Peter (Uddevalla Hospital) ; Laribi, Kamel (Centre Hospitalier du Mans) ; Meddeb, Balkis (Aziza Othmana University Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Raposo, Joäo (Hospital de Santa Maria) ; Schuh, Anna (Oxford University Hospitals) ; Ünal, Ali (Erciyes University Medical School) ; Widenius, Tom (Peijas Hospital) ; Bernhardt, Alf (F. Hoffmann-La Roche Ltd) ; Kellershohn, Kerstin (Roche Pharma AG) ; Messeri, Dimitri (F. Hoffmann-La Roche Ltd) ; Osborne, Stuart (F. Hoffmann-La Roche Ltd) ; Leblond, Véronique (UPMC University) ; Universitat Autònoma de Barcelona
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. [...]
2018 - 10.3324/haematol.2017.170480
Haematologica, Vol. 103 Núm. 4 (23 2018) , p. 698-706  
9.
10 p, 8.5 MB Introducing Design Strategies to Preserve N-Heterocycles Throughout the On-Surface Synthesis of Graphene Nanostructures / Tenorio, María José (Institut Català de Nanociència i Nanotecnologia) ; Moreno, Cesar (Institut Català de Nanociència i Nanotecnologia) ; Vilas-Varela, Manuel (Universidade de Santiago de Compostela) ; Castro-Esteban, Jesús (Universidade de Santiago de Compostela. Departamento de Química Orgánica) ; Febrer Calabozo, Pol (Institut Català de Nanociència i Nanotecnologia) ; Pruneda, Miguel (Institut Català de Nanociència i Nanotecnologia) ; Peña, Diego (Universidade de Santiago de Compostela) ; Mugarza, Aitor (Institut Català de Nanociència i Nanotecnologia)
Despite the impressive advances in the synthesis of atomically precise graphene nanostructures witnessed during the last decade, advancing in compositional complexity faces major challenges. The concept of introducing the desired functional groups or dopants in the molecular precursor often fails due to their lack of stability during the reaction path. [...]
2023 - 10.1002/smtd.202300768
Small Methods, (October 2023) , art. 2300768  
10.
9 p, 996.2 KB Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2 / Barr, Paul M. (University of Rochester) ; Robak, Tadeusz (Medical University of Lodz) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ; Bartlett, Nancy L. (Washington University School of Medicine) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E (Stanford University School of Medicine) ; Devereux, Stephen (Kings College Hospital) ; Grosicki, Sebastian (School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Li, Jianyong (Jiangsu Province Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ; Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ; James, Danelle (Pharmacyclics. LLC an AbbVie Company) ; Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510  

Dipòsit Digital de Documents de la UAB : 157 registres trobats   1 - 10següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.